Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 917,876 | 1,019,491 | 812,700 | 792,065 | 744,313 |
| Marketable Securities | 765,642 | 605,461 | 596,800 | 586,879 | 523,537 |
| Receivables | 2,039,247 | 1,943,932 | 1,974,300 | 1,971,449 | 1,844,547 |
| Inventories | 928,553 | 820,397 | 726,100 | 641,588 | 554,320 |
| TOTAL | $4,814,917 | $4,544,732 | $4,335,000 | $4,135,742 | $3,860,051 |
| Non-Current Assets | |||||
| PPE Net | 2,461,614 | 2,394,727 | 2,358,600 | 2,274,529 | 2,261,702 |
| Investments And Advances | 2,044,703 | 1,821,985 | 1,486,500 | 1,327,303 | 1,064,677 |
| Other Non-Current Assets | 630,746 | 611,252 | 584,200 | 963,641 | 919,943 |
| TOTAL | $5,137,063 | $4,827,964 | $4,429,300 | $4,565,473 | $4,246,322 |
| Total Assets | $9,951,980 | $9,372,696 | $8,764,300 | $8,701,215 | $8,106,373 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 171,906 | 207,611 | 178,200 | 818,426 | 716,364 |
| Other current liabilities | 670,709 | 666,216 | 637,200 | 334 | 397 |
| TOTAL | $1,331,190 | $1,265,740 | $1,135,500 | $1,138,628 | $1,029,017 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 488,575 | 391,913 | 320,100 | 319,868 | 312,256 |
| aiOther Non-Current Liabilities | 190,020 | 169,922 | 152,000 | 125,225 | 115,920 |
| TOTAL | $1,434,364 | $1,539,312 | $1,484,700 | $1,510,994 | $1,556,618 |
| Total Liabilities | $2,765,554 | $2,805,052 | $2,620,200 | $2,649,622 | $2,585,635 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 108,056 | 107,861 | 107,697 | 107,440 | 107,152 |
| Common Shares | 112 | 112 | 100 | 111 | 111 |
| Retained earnings | 3,839,179 | 3,287,767 | 2,946,700 | 2,773,214 | 2,384,897 |
| Other shareholders' equity | -11,464 | -15,834 | 400 | 23,595 | 2,108 |
| TOTAL | $7,186,426 | $6,567,644 | $6,144,100 | $6,051,593 | $5,520,738 |
| Total Liabilities And Equity | $9,951,980 | $9,372,696 | $8,764,300 | $8,701,215 | $8,106,373 |